Results 71 to 80 of about 5,084 (185)

BTLA-Expressing Dendritic Cells in Patients With Tuberculosis Exhibit Reduced Production of IL-12/IFN-α and Increased Production of IL-4 and TGF-β, Favoring Th2 and Foxp3+ Treg Polarization

Frontiers in Immunology, 2020
Little is known about how tuberculosis (TB) impairs dendritic cell (DC) function and anti-TB immune responses. We previously showed that the B and T lymphocyte attenuator (BTLA), an immune inhibitory receptor, is involved in TB pathogenesis.
Jun-Ai Zhang, Jun-Ai Zhang, Yuan-Bin Lu, Yuan-Bin Lu, Wan-Dang Wang, Wan-Dang Wang, Gan-Bin Liu, Chen Chen, Chen Chen, Ling Shen, Hou-Long Luo, Hou-Long Luo, Huan Xu, Huan Xu, Ying Peng, Ying Peng, Hong Luo, Hong Luo, Gui-Xian Huang, Gui-Xian Huang, Du-Du Wu, Bi-Ying Zheng, Lai-Long Yi, Zheng W. Chen, Jun-Fa Xu, Jun-Fa Xu   +25 more
doaj   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, Volume 13, Issue 35, 24 June 2026.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination [PDF]

, 2010
The function of antigen-specific CD8+ T cells, which may protect against both infectious and malignant diseases, can be impaired by ligation of their inhibitory receptors, which include CTL-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1).
Camilla Jandus, Michielin, O., Jandus, C., Jandus, Camilla, Derré, L., Derré, Laurent, Pastor, Sonia, Michielin, Olivier, Daniel Olive, Laurent Derré, Olive, D., Daniel E. Speiser, Rivals, Jean-Paul, Rivals, J.P., Pastor, S., Romero, P., Speiser, D.E., Sonia Pastor, Pedro Romero, Speiser, Daniel E, Jean-Paul Rivals, Olivier Michielin, Donata Rimoldi, Rimoldi, Donata, Olive, Daniel, Romero, Pedro, Rimoldi, D.   +26 more
core   +2 more sources

Funktionelle Studien am B- und T-Lymphozyten Attenuator (BTLA) in der Jurkat Zelllinie

, 2014
Die T-Zell-Aktivierung ist ein komplexer Prozess, an dem viele Rezeptoren und Liganden beteiligt sind. Eine wichtige Aufgabe in diesem Prozess haben, neben dem antigen-spezifischen Signal (Signal 1), die sogenannten Kosignale (Signal 2).
Wildom, Bernhard
core   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells

Frontiers in Immunology, 2019
Objectives: The activation and inhibition of T-cells has been well-studied under physiological conditions. Co-inhibition is an important mechanism to keep effector T-cells in check.
Kai Werner, Sebastian Dolff, Yang Dai, Xin Ma, Alexandra Brinkhoff, Johannes Korth, Anja Gäckler, Hana Rohn, Ming Sun, Jan Willem Cohen Tervaert, Pieter van Paassen, Andreas Kribben, Oliver Witzke, Benjamin Wilde   +13 more
doaj   +1 more source

B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts

Immunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Atherosclerotic cardiovascular disease (ASCVD) is increasingly recognized not just as a lipid‐driven disease, but as a complex interplay between vascular cells and the immune system. Accumulating evidence highlights a central, yet heterogeneous role for B cells in atherogenesis, with distinct subsets displaying opposing roles.
Sophieke Lems, Megan Grace Mazzei, Amanda C. Foks, Coleen A. McNamara   +3 more
wiley   +1 more source

Mixing signals: Molecular turn ons and turn offs for innate γδ Τ cells

Frontiers in Immunology, 2014
Lymphocytes of the gamma delta (γδ) T cell lineage are evolutionary conserved and although they express rearranged antigen-specific receptors a large proportion respond as innate effectors. γδ T cells are poised to combat infection by responding rapidly
Vasileios eBekiaris, Vasileios eBekiaris, John S Šedý, Carl F Ware   +3 more
doaj   +1 more source

Inflammation‐Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity

Immunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Lymphoid structures (LS) arising in nonlymphoid tissues are increasingly recognized as active immune niches rather than simple consequences of chronic inflammation. In this review, we propose a framework that distinguishes inflammatory lymphoid structures (ILS) from mature tertiary lymphoid structures (mTLS), while acknowledging that these ...
Marie Frutoso, Emie Delmas, Rudolf Corty, Eleonore Bettacchioli, Divi Cornec, Sophie Hillion, Soizic Garaud   +6 more
wiley   +1 more source